Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Conavi Medical ( (TSE:CNVI) ) has shared an announcement.
Conavi Medical announced a case report published in the Journal of the Society for Cardiovascular Angiography & Interventions, showcasing the effectiveness of its Novasight™ Hybrid Imaging System in a complex coronary case. The report highlights how the system’s integration of IVUS and OCT enabled precise diagnosis and treatment, aligning with new U.S. imaging guidelines and addressing long-standing adoption barriers. This advancement underscores Conavi’s commitment to enhancing precision-guided interventional cardiology and improving patient outcomes.
The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.
More about Conavi Medical
Conavi Medical is a company specializing in the design, manufacture, and marketing of imaging technologies for minimally invasive cardiovascular procedures. Its flagship product, the Novasight Hybrid™ System, uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries. The system has received regulatory approvals in the U.S., Canada, China, and Japan.
Average Trading Volume: 65,392
Technical Sentiment Signal: Sell
Current Market Cap: C$27.26M
For a thorough assessment of CNVI stock, go to TipRanks’ Stock Analysis page.